NCT06007651

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of LY3885125 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With NAFLD

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a total of approximately 111 weeks.

Conditions

• Dyslipidemias
• Non-Alcoholic Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	LY3885125	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2023-08-10
• Primary completion: 2025-02-12
• Completion: 2025-02-12
• First posted: 2023-08-23
• Last updated: 2026-04-13
• Results posted: 2026-04-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study